Clinical trial · Observational
AI Multimodal Model for Predicting CRPC Progression Risk
Artificial Intelligence for Predicting Progression Risk of Castration-Resistant Prostate Cancer by Integrating Multimodal Data: A Multicenter, Retrospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to develop an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing castration-resistant prostate cancer (CRPC), a more severe form of the disease. The study will use pre-treatment MRI images, biopsy pathology slides, and clinical data collected from patients who received either hormone therapy (ADT) or radical prostatectomy surgery. By integrating these different types of data, the AI model is designed to help doctors identify high-risk patients earlier, personalize treatment plans, and ultimately improve patient outcomes. This is a multicenter, retrospective study that will analyze data from over 500 patients with at least 24 months of follow-up. The performance of the model will be evaluated using standard accuracy metrics.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Castration-Resistant Prostate Cancer | Castration-Resistant Prostate Carcinoma | ALIAS | 0.90 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- ADT Treatment Group
- description
- Patients with newly diagnosed advanced prostate cancer who received at least 6 months of androgen deprivation therapy.
- label
- Radical Prostatectomy Group
- description
- Patients with localized or locally advanced prostate cancer who underwent radical prostatectomy.
Primary outcomes (2)
- measure
- Prediction of CRPC Progression Risk in the ADT Treatment Group
- timeFrame
- Minimum 24 months of follow-up
- description
- Performance of the multimodal AI model in predicting progression to castration-resistant prostate cancer in patients with newly diagnosed advanced prostate cancer who received at least 6 months of androgen deprivation therapy. Metrics include AUC, accuracy, sensitivity, and specificity.
- measure
- Prediction of CRPC Progression Risk in the Radical Prostatectomy Group
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * (1) Male, age ≥18 years; (2) Pathologically confirmed newly diagnosed advanced prostate cancer; (3) Received at least 6 months of androgen deprivation therapy OR underwent radical prostatectomy; (4) Have complete baseline MRI (T2WI, DWI, ADC) and biopsy pathology data; (5) Have complete follow-up records (at least 24 months). Exclusion Criteria: * (1) Missing clinical information; (2) MRI images of poor quality or missing key sequences; (3) Poor quality pathological specimens; (4) Lost to follow-up or incomplete data during follow-up; (5) Concurrent other malignant tumors; (6) Prior anti-tumor therapy.
References
Publications (0)
Data not yet available